ISCDD Celebrates 15th Anniversary of Improving CNS Drug Development Through Collaboration Amongst Stakeholders

LAS VEGAS, March 22, 2017 /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD) is celebrating its 15^th anniversary at the ISCDD 2017 Annual Meeting, March 22^nd—24^th, in Las Vegas, Nevada.  For 15 years, the ISCDD, a non-profit, independent society, has brought together the leading CNS drug developers, along with academic and regulatory leaders, to improve CNS drug development.

In celebration of its 15^th anniversary, the ISCDD is hosting several special events at the Annual Meeting.  These include a special ISCDD Drug Developers Studio featuring previous ISCDD award winners Antony Loebel, Sunovion Pharmaceuticals, Raymond Sanchez, Otsuka Pharmaceutical, Steve Romano, Mallinckrodt Pharmaceuticals, Jay Kranzler, Regenovation, and chaired by Dr. George Garibaldi, the Chairman of the ISCDD Executive Committee, and Dr. Amir Kalali, Executive Secretary, ISCDD, as well as an Investor Roundtable, and a special session on future technologies.

"For fifteen years, ISCDD has brought together a team of selfless and thoughtful influencers of CNS therapy development," Dr. George Garibaldi said of the occasion of the 15^th anniversary.  "Our strategic focus is to enable the discovery and development of novel therapies to patients suffering from brain disorders. I believe that the society has continuously played a significant role in shaping the present and future of health care."

Dr. Amir Kalali said, "Fifteen years ago, when a group of us founded ISCDD, the concept of scientific collaboration was a novel one in the pharmaceutical industry.  We believe strongly that pre-competitive collaboration helps us bring treatments to patients faster and more efficiently.  It has been a pleasure to witness the spirit of collaboration for the good of our patients grow throughout our history."

The International Society for CNS Drug Development (ISCDD) is a non-profit, independent leadership forum founded in 2002 to improve central nervous system drug development through collaboration amongst stakeholders including industry, academia, and government.

For more information, please contact:

Erica Moore
ISCDD Secretariat
O: 702-992-0784
M: 610-613-3524
[email protected]

SOURCE ISCDD